Can ocrelizumab tame MS inflammation from the start? new study aims to find out
NCT ID NCT04466150
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocrelizumab and have their spinal fluid checked before and after three years of treatment. The goal is to see if early treatment can reduce chronic inflammation in the central nervous system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ocrelizumab (Ocrevus)
- What this could lead to
- If successful, this could show that early treatment with ocrelizumab reduces long-term inflammation in the central nervous system, potentially slowing MS progression.
- What could go wrong
- This is a small, early-phase biomarker study with only 30 participants and no placebo group. It measures lab markers, not clinical outcomes, so benefits for patients remain uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICALLY ISOLATED SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Francisco
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Could a simple injection replace an IV for MS treatment?
- Can a new injection tame relapsing MS?
- Timing of MS drug may change disease course
- Massive italian MS registry aims to unlock secrets of the disease
- MS patients switch drugs to save immune defenses